Extended Follow-up Results From CheckMate 274: Adjuvant Nivolumab in MIUC

Video

Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.

Related Videos
Joaquim Bellmunt, MD, PhD
Nikhil A. Gopal, MD
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Samer A. Srour, MB ChB, MS
Vikram Narayan, MD
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Samer A. Srour, MB ChB, MS
Scott T. Tagawa, MD, MS, FACP, FASCO
Samer A. Srour, MB ChB, MS
Related Content
Jonathan E. Rosenberg, MD

ADCs and Immunotherapy Broaden the Bladder Cancer Treatment Paradigm

May 2nd 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Samer A. Srour, MB ChB, MS

Early Responses With CTX130 Renew Hope for Anti-CD70 CAR T-Cell Therapy in Advanced RCC

April 29th 2024
Article
Terence Friedlander, MD

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

April 24th 2023
Podcast
FDA

FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for BCG-Unresponsive NMIBC

April 22nd 2024
Article
Paul V. Viscuse, MD, of the University of Virginia

Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care

April 22nd 2024
Article